JP7688480B2 - Ｂ型肝炎ウイルス（ｈｂｖ）感染を有する対象を処置する方法 - Google Patents

Ｂ型肝炎ウイルス（ｈｂｖ）感染を有する対象を処置する方法 Download PDF

Info

Publication number
JP7688480B2
JP7688480B2 JP2019556314A JP2019556314A JP7688480B2 JP 7688480 B2 JP7688480 B2 JP 7688480B2 JP 2019556314 A JP2019556314 A JP 2019556314A JP 2019556314 A JP2019556314 A JP 2019556314A JP 7688480 B2 JP7688480 B2 JP 7688480B2
Authority
JP
Japan
Prior art keywords
hbv
rnai agent
subject
hbsag
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019556314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516673A5 (https=
JP2020516673A (ja
Inventor
ローラ・セップ－ロレンジノ
ウルリケ・プロツァー
トーマス・ミヒラー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technische Universitaet Muenchen
Alnylam Pharmaceuticals Inc
Original Assignee
Technische Universitaet Muenchen
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universitaet Muenchen, Alnylam Pharmaceuticals Inc filed Critical Technische Universitaet Muenchen
Priority claimed from PCT/US2018/028116 external-priority patent/WO2018195165A1/en
Publication of JP2020516673A publication Critical patent/JP2020516673A/ja
Publication of JP2020516673A5 publication Critical patent/JP2020516673A5/ja
Priority to JP2023088820A priority Critical patent/JP2023123449A/ja
Application granted granted Critical
Publication of JP7688480B2 publication Critical patent/JP7688480B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2019556314A 2017-04-18 2018-04-18 Ｂ型肝炎ウイルス（ｈｂｖ）感染を有する対象を処置する方法 Active JP7688480B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023088820A JP2023123449A (ja) 2017-04-18 2023-05-30 Ｂ型肝炎ウイルス（ｈｂｖ）感染を有する対象を処置する方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762486618P 2017-04-18 2017-04-18
US62/486,618 2017-04-18
US201762553358P 2017-09-01 2017-09-01
US62/553,358 2017-09-01
US201862646978P 2018-03-23 2018-03-23
US62/646,978 2018-03-23
PCT/US2018/028116 WO2018195165A1 (en) 2017-04-18 2018-04-18 Methods for the treatment of subjects having a hepatitis b virus (hbv) infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023088820A Division JP2023123449A (ja) 2017-04-18 2023-05-30 Ｂ型肝炎ウイルス（ｈｂｖ）感染を有する対象を処置する方法

Publications (3)

Publication Number Publication Date
JP2020516673A JP2020516673A (ja) 2020-06-11
JP2020516673A5 JP2020516673A5 (https=) 2021-05-27
JP7688480B2 true JP7688480B2 (ja) 2025-06-04

Family

ID=71013269

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019556314A Active JP7688480B2 (ja) 2017-04-18 2018-04-18 Ｂ型肝炎ウイルス（ｈｂｖ）感染を有する対象を処置する方法
JP2023088820A Pending JP2023123449A (ja) 2017-04-18 2023-05-30 Ｂ型肝炎ウイルス（ｈｂｖ）感染を有する対象を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023088820A Pending JP2023123449A (ja) 2017-04-18 2023-05-30 Ｂ型肝炎ウイルス（ｈｂｖ）感染を有する対象を処置する方法

Country Status (1)

Country Link
JP (2) JP7688480B2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114507663A (zh) * 2020-11-16 2022-05-17 浙江柏拉阿图医药科技有限公司 寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用
CN118660708A (zh) * 2022-01-25 2024-09-17 公益财团法人川崎市产业振兴财团 用于经皮给药的含有rna的组合物和该组合物的给药方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016077321A1 (en) 2014-11-10 2016-05-19 Alnylam Pharmaceuticals, Inc. Hepatitis b virus (hbv) irna compositions and methods of use thereof
WO2017121791A1 (en) 2016-01-12 2017-07-20 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Means and methods for treating hbv

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016077321A1 (en) 2014-11-10 2016-05-19 Alnylam Pharmaceuticals, Inc. Hepatitis b virus (hbv) irna compositions and methods of use thereof
WO2017121791A1 (en) 2016-01-12 2017-07-20 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Means and methods for treating hbv

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. Hepatol. (2016) vol.64, issue 2,suppl. p.S148-S149(PS026)
J. Hepatol. (Jan 2017) vol.66, issue 1,suppl. p.S112(LBP-538)
Vaccine (2016) vol.34, issue 7, p.923-932

Also Published As

Publication number Publication date
JP2020516673A (ja) 2020-06-11
JP2023123449A (ja) 2023-09-05

Similar Documents

Publication Publication Date Title
KR102720270B1 (ko) B형 간염 바이러스 (hbv)에 감염된 대상체의 치료 방법
JP7426973B2 (ja) Ｂ型肝炎ウイルス（ＨＢＶ）ｉＲＮＡ組成物及びその使用方法
US11324820B2 (en) Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
JP2023123449A (ja) Ｂ型肝炎ウイルス（ｈｂｖ）感染を有する対象を処置する方法
OA19808A (en) Methods for the treatment of subjects having a hepatitis B virus (HBV) infection.
HK40023840A (en) Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
HK40023840B (zh) 具有乙肝病毒(hbv)感染的受试者的治疗方法
HK40061918A (en) Hepatitis b virus (hbv) irna compositions and methods of use thereof
HK1255502B (en) Hepatitis b virus (hbv) irna compositions and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220426

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221020

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230530

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230630

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230721

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250523

R150 Certificate of patent or registration of utility model

Ref document number: 7688480

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150